News

AddToAny

Google+ Facebook Twitter Twitter

Biomarker for bladder cancer

A new diagnostic technique has revealed a protein biomarker that accurately differentiates bladder cancer from benign inflammation.

p10-13-news-neutrophil-white_blood_cell-science-photo-library-f0224299.jpg

Label-free digital pathology using infrared imaging, with subsequent proteomic analysis, was used to discover the first protein biomarker (AHNAK2) for bladder cancer.

AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ), which is challenging to diagnose.

A new report describes this diagnostic procedure, which is label-free, automated, observer-independent, and as sensitive and specific as established histopathological methods.  

Image credit | Science Photo Library 

Related Articles

Ebola breakthrough

Ebola could soon be “preventable and treatable”, after a trial of two drugs showed significantly improved survival rates.

Targeting the spread of pancreatic cancer

An international team of scientists has revealed how aggressive pancreatic cancer cells change their environment to enable metastasis – the main cause of pancreatic cancer-related death.

 p10-13-news-prostate-cancer-science-photo-library-f0202638.jpg

Urine test for prostate cancer

Scientists have developed a urine test to diagnose aggressive prostate cancer and predict whether patients will require treatment up to five years earlier than standard clinical methods.

p8-13-news-car-t-cell-therapy-science-photo-library-c0388808.jpg

High hopes for pioneering CAR-T

NHS patients with lymphoma have been given a pioneering treatment that genetically reprogrammes their immune system to fight cancer.

Top